Of education and public policy: Aducanumab

J Am Geriatr Soc. 2022 Jan;70(1):81-84. doi: 10.1111/jgs.17523. Epub 2021 Nov 3.

Authors

Nancy E Lundebjerg¹, Peter A Hollmann², Mark A Supiano^{3

4}

Affiliations

¹ American Geriatrics Society, New York, New York, USA.
² Division of Geriatrics, Brown Medicine, Providence, Rhode Island, USA.
³ Division of Geriatrics, Spencer Fox Eccles School of Medicine, Salt Lake City, Utah, USA.
⁴ University of Utah Center on Aging, Salt Lake City, Utah, USA.

PMID: 34674219
DOI: 10.1111/jgs.17523

No abstract available

Publication types

Editorial

MeSH terms

Alzheimer Disease / drug therapy*
Antibodies, Monoclonal, Humanized / therapeutic use*
Drug Approval*
Drug-Related Side Effects and Adverse Reactions
Humans
Product Surveillance, Postmarketing
Public Policy
United States
United States Food and Drug Administration

Substances

Antibodies, Monoclonal, Humanized
aducanumab